An arrhythmogenic metabolite in atrial fibrillation

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Dokumenter

  • Fulltext

    Forlagets udgivne version, 1,87 MB, PDF-dokument

  • Julia Krause
  • Alexander Nickel
  • Alexandra Madsen
  • Hamish M. Aitken-Buck
  • A. M.Stella Stoter
  • Jessica Schrapers
  • Francisco Ojeda
  • Kira Geiger
  • Melanie Kern
  • Michael Kohlhaas
  • Edoardo Bertero
  • Patrick Hofmockel
  • Florian Hübner
  • Ines Assum
  • Matthias Heinig
  • Christian Müller
  • Arne Hansen
  • Tobias Krause
  • Deung Dae Park
  • Steffen Just
  • Dylan Aïssi
  • Daniela Börnigen
  • Diana Lindner
  • Nele Friedrich
  • Khaled Alhussini
  • Constanze Bening
  • Renate B. Schnabel
  • Mahir Karakas
  • Licia Iacoviello
  • Veikko Salomaa
  • Hugh Tunstall-Pedoe
  • Kari Kuulasmaa
  • Paulus Kirchhof
  • Stefan Blankenberg
  • Torsten Christ
  • Thomas Eschenhagen
  • Regis R. Lamberts
  • Christoph Maack
  • Justus Stenzig
  • Tanja Zeller
Background
Long-chain acyl-carnitines (ACs) are potential arrhythmogenic metabolites. Their role in atrial fibrillation (AF) remains incompletely understood. Using a systems medicine approach, we assessed the contribution of C18:1AC to AF by analysing its in vitro effects on cardiac electrophysiology and metabolism, and translated our findings into the human setting.

Methods and results
Human iPSC-derived engineered heart tissue was exposed to C18:1AC. A biphasic effect on contractile force was observed: short exposure enhanced contractile force, but elicited spontaneous contractions and impaired Ca2+ handling. Continuous exposure provoked an impairment of contractile force. In human atrial mitochondria from AF individuals, C18:1AC inhibited respiration. In a population-based cohort as well as a cohort of patients, high C18:1AC serum concentrations were associated with the incidence and prevalence of AF.

Conclusion
Our data provide evidence for an arrhythmogenic potential of the metabolite C18:1AC. The metabolite interferes with mitochondrial metabolism, thereby contributing to contractile dysfunction and shows predictive potential as novel circulating biomarker for risk of AF.
OriginalsprogEngelsk
Artikelnummer566
TidsskriftJournal of Translational Medicine
Vol/bind21
Udgave nummer1
Antal sider16
ISSN1479-5876
DOI
StatusUdgivet - 2023

Bibliografisk note

Funding Information:
Open access funding enabled and organized by project DEAL. This work was supported by grants from the German Research Foundation (DFG, STE 2596/4-1/ZE 1098/10-1), the Federal Ministry of Education and Research (BMBF) e:Med symAtrial (FKZ: 01ZX1408A,B,C), e:Med Confirm (FKZ:01ZX1708A,C,G), German Center for Cardiovascular Research (DZHK, FKZs: 81Z0710102, 81X2710174, and 80714/156/2-5-2), BiomarCaRE/MORGAM (European Commission Seventh Framework Programme FP7/2007–2013 under grant agreement no. HEALTH-F2-2011-278913), ERA-CVD PREMED-CAD (European Research Area Network on Cardiovascular Diseases Precision Medicine in Coronary Artery Disease, FKZ.01KL1807). TZ was additionally supported by the DZHK (FKZ 81Z0710102, 2018–2025). VS was supported by the Finnish Foundation for Cardiovascular Research and by the Juho Vainio Foundation. CMa is supported by the German Research Foundation (DFG; Ma 2528/7-1; Ma 2528/8-1; SFB 894; TRR-219; SFB 1525, Projekt #453989101), Federal Ministry of Education and Research (BMBF, 01EO1504) and Barth Syndrome Foundation. Human trabeculae work was supported by The Heart Foundation of New Zealand (Grant no. 1766). AM was supported by the German Research Foundation (DFG, 386103693) and the European Research Council (IndivuHeart, NCT02417311). RBS has received funding from the European Research Council (ERC) under the European Union’s Horizon 2020 Research and Innovation Programme under the grant agreement no. 648131, from the European Union’s Horizon 2020 Research and Innovation Programme under the grant agreement no. 847770 (AFFECT-EU), DZHK (81Z1710103), Federal Ministry of Education and Research (BMBF, 01ZX1408A), and ERACoSysMed3 (031L0239).

Funding Information:
We would like to thank Tim Hartmann, Grit Höppner, Birgit Klampe, Thomas Schulze, Sarah Schweingruber, Anja Sauer, Alice Schaaf, and Caroline Röthemeier for expert technical assistance as well as Bärbel M. Ulmer for hiPSC line generation. Moreover, we would like to thank Kristin Hartmann from the Mouse Pathology Core facility at the UKE for histological staining, the UKE FACS core facility for support with flow cytometry, and the UKE Microscopy Imaging facility. Finally, we also want to thank all participants of the cohort studies. We acknowledge financial support from the Open Access Publication Fund of UKE - Universitätsklinikum Hamburg-Eppendorf and DFG – German Research Foundation.

Publisher Copyright:
© 2023, BioMed Central Ltd., part of Springer Nature.

ID: 374562531